A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility
Open Access
- 16 November 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 22 (3) , 792-797
Abstract
BACKGROUND: Controlled ovarian hyperstimulation with intrauterine insemination (IUI) is a widely accepted treatment for unexplained and male subfertility. No consensus exists about the drug of first choice to be used as hyperstimulation. This randomized multicentre trial using a parallel design compares the efficacy of clomiphene citrate (CC) with that of recombinant FSH (rFSH). METHODS: Couples with primary unexplained or male subfertility were randomized to receive CC or rFSH for ovarian hyperstimulation. The treatment was continued for up to four cycles unless pregnancy occurred. Cycles with more than three follicles were cancelled. Cumulative pregnancy rates and live birth rates were primary outcomes. Cancellation during treatment and multiple birth rates are secondary outcomes. Results were analysed following the intention-to-treat principle. RESULTS: Seventy couples with male subfertility and 68 couples with unexplained subfertility were included. Seventy-one women received CC, and 67 received rFSH. Twenty-seven pregnancies were observed in the CC group (38%) and 23 in the rFSH group (34.3%) relative risk (RR) 1.11 [95% confidence interval (95% CI) 0.71–1.73]. The live birth rate was 28.2% (20/71) and 26.9% (18/67) for CC and rFSH, respectively, RR 1.05 (95% CI 0.61–1.80). Overall, the live birth rates per cycle were 10% for CC-stimulated and 8.7% for rFSH stimulated cycles. The total multiple pregnancy rate was 6.0%. Thirty-five cycles (8.6%) were cancelled because of four or more follicles (CC, n = 17; rFSH, n = 18). CONCLUSIONS: In couples with primary unexplained or male subfertility participating in an IUI program, ovarian hyperstimulation can be achieved by CC or rFSH. No significant difference in live birth rates between CC and rFSH was observed. Being less expensive, CC seems the more cost-effective drug and therefore, can be offered as drug of first choice.Keywords
This publication has 10 references indexed in Scilit:
- Should We Continue Performing Intrauterine Inseminations in the Year 2004?Gynecologic and Obstetric Investigation, 2005
- Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSHHuman Reproduction, 2002
- Oral versus injectable ovulation induction agents for unexplained subfertilityCochrane Database of Systematic Reviews, 2002
- Recombinant human FSH versus highly purified urinary FSH: a randomized study in intrauterine insemination with husbands' spermatozoaHuman Reproduction, 2000
- A randomized prospective study comparing pregnancy rates after clomiphene citrate and human menopausal gonadotropin before intrauterine inseminationFertility and Sterility, 2000
- Timed intercourse versus intra-uterine insemination with or without ovarian hyperstimulation for subfertility in men1999
- Intrauterine insemination treatment in subfertility: an analysis of factors affecting outcomeHuman Reproduction, 1999
- Efficacy of Superovulation and Intrauterine Insemination in the Treatment of InfertilityNew England Journal of Medicine, 1999
- The effectiveness of ovulation induction and intrauterine insemination in the treatment of persistent infertility: a meta-analysisHuman Reproduction, 1997
- Evaluation of clomiphene citrate and human chorionic gonadotropin treatment: a prospective, randomized, crossover study during intrauterine insemination cyclesFertility and Sterility, 1994